WO2015165413A1 - 一种新型的稳定型抗体药物耦联物及其制备方法和用途 - Google Patents

一种新型的稳定型抗体药物耦联物及其制备方法和用途 Download PDF

Info

Publication number
WO2015165413A1
WO2015165413A1 PCT/CN2015/077887 CN2015077887W WO2015165413A1 WO 2015165413 A1 WO2015165413 A1 WO 2015165413A1 CN 2015077887 W CN2015077887 W CN 2015077887W WO 2015165413 A1 WO2015165413 A1 WO 2015165413A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
group
integer
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/077887
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
WO2015165413A8 (zh
Inventor
秦刚
袁金铎
谭初兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP19157398.9A priority Critical patent/EP3517114A1/en
Priority to AU2015252518A priority patent/AU2015252518B2/en
Priority to JP2016563404A priority patent/JP6666264B2/ja
Priority to EP15786402.6A priority patent/EP3138568B1/en
Priority to KR1020167033391A priority patent/KR102511249B1/ko
Priority to US15/307,738 priority patent/US11040084B2/en
Priority to ES15786402T priority patent/ES2736505T3/es
Application filed by Individual filed Critical Individual
Priority to CN201580023609.3A priority patent/CN106856656B/zh
Priority to CN202110225700.0A priority patent/CN112999362B/zh
Publication of WO2015165413A1 publication Critical patent/WO2015165413A1/zh
Publication of WO2015165413A8 publication Critical patent/WO2015165413A8/zh
Anticipated expiration legal-status Critical
Priority to AU2020200975A priority patent/AU2020200975B2/en
Priority to US17/180,645 priority patent/US11911435B2/en
Priority to US17/180,412 priority patent/US11911434B2/en
Priority to US18/408,826 priority patent/US20240156894A1/en
Priority to US18/410,200 priority patent/US20240165192A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the invention belongs to the field of biopharmaceutical and biotechnology, and particularly relates to a novel linker (linker, also called a coupling agent) having a coupling function, a novel linker-cytotoxin intermediate having a ring opening stable structure and preparation thereof, It is also applied to a method in which a small molecule compound, a nucleic acid, a nucleic acid analog, a tracer molecule or the like is stably coupled to a C-terminus of a protein or a polypeptide in a site-specific manner.
  • the linker and the coupling method of the invention can be used for preparing ADC drugs for tumor targeted therapy, targeted tracer diagnostic reagents, and efficient delivery reagents for specific cell types.
  • the ADC drug prepared by the present invention has a stable ring-opening structure, a specific drug loading amount, and reproducible pharmacokinetic data. It fundamentally solves the two problems of stability and heterogeneity that plague ADC drugs. Specifically, it relates to a novel anti-human ErbB2/Her2 antibody-maytansin derivative coupling, a novel anti-human ErbB2/Her2 antibody-olisdaltin derivative coupling, a preparation method thereof and an ErbB2/Her2 positive tumor thereof Targeted therapy.
  • ADC Antibody-Drug Conjugates
  • the mechanism of action of the ADC drug is as follows: the antibody or antibody ligand specifically recognizes and binds to an antigen on the cell surface; the formed conjugate enters the cell by endocytosis while bringing the small molecule drug; the antibody is enzymatically or The linker itself cleaves and the small molecule drug is released into the cell in a suitable active form, killing the target cell.
  • the small molecule cytotoxic drugs used in ADC drugs are very active, and are usually 10-1000 times more active than the currently used chemotherapeutic drugs.
  • the ADC drug consists of an antibody, a linker, and a toxin.
  • the antibody determines the cell type and target of the drug;
  • the cytotoxin can be any compound that can cause cell death, induce apoptosis or reduce cell viability; and
  • the linker is a bridge that combines the two, is the ADC
  • the core part of drug design is the key to achieving targeted drug delivery.
  • the linkers used in ADC drugs are classified into both rupturable and non-breakable types.
  • Ideal linker To meet the following requirements: sufficient stability outside the cell to ensure that the small molecule drug is not detached from the ligand; after entering the cell, the cleavable linker ruptures under appropriate conditions, releasing the active small molecule drug; for non-breakable
  • the linker, the active ingredient is composed of a small molecule, a linker, and an amino acid residue produced by enzymatic hydrolysis of the ligand.
  • the linker links the antibody to a small molecule cytotoxin. If the cytotoxin falls off before reaching the target, it will cause toxicity to normal tissues, and on the other hand, reduce the efficacy of the ADC drug reaching the target. Therefore, in the development of ADC drugs, the design of linker and coupling strategy is critical, not only plays a key role in the stability of ADC drugs, but also directly affects the bioactivity, polymerization state, bioavailability and in vivo of the coupling. Distribution and metabolism. Among the currently marketed and clinical ADC drugs, the structure and coupling strategies of the linkers are mostly derived from the two companies, Seattle Genetics and Immunogen.
  • thiosuccinimide structures can be ring-open hydrolysis by promoting hydrolysis. After ring opening, the thiosuccinamide structure cannot exchange reaction with the thiol group in the body (Fig. 1, schematic diagram of ring opening reaction), thereby improving the in vivo stability of the ADC drug.
  • the open-loop conditions that can be selected in traditional chemical methods are: alkaline treatment, molybdate treatment, etc. (Kalia J et al., 2007), but these conditions cannot be directly applied to the ring-opening reaction of the succinimide ring in ADC drugs. This is because the above treatment conditions are too severe and cause serious irreversible damage to proteins (antibodies), so the conditions cannot be directly applied to the ring-opening reaction of the succinimide ring in the ADC drug.
  • ErbB2/Her2 antigen is a mammalian epidermal growth factor receptor transmembrane receptor family including humans One of the members is highly expressed on the surface of approximately 20% of breast cancers and 16% of gastric cancer cells (Slamon et al. 1987, Science, Vol 235: 177-182).
  • the invention relates to a novel coupling functional linker (also known as a coupling agent), a linker-loading intermediate, and a ring opening reaction and a preparation method thereof.
  • the present invention also relates to a coupling that stably couples the C-terminus of a protein or polypeptide to a linker-loading substance intermediate in a site-specific manner, and a method of producing the same.
  • the invention further relates to a pharmaceutical composition comprising the coupling.
  • the invention further relates to the use of the coupling or a pharmaceutical composition comprising the same in the treatment or prevention of a disease.
  • the invention provides a compound of formula (I), formula (II), formula (III) or formula (IV) or a pharmaceutically acceptable salt thereof:
  • PCA is a specific substrate recognition sequence of ligase.
  • the ligase is an enzyme that catalyzes the binding of two molecules together by a new chemical bond.
  • the ligase refers to a transpeptidase, including but not limited to various natural Sortase enzymes and various novel transpeptidases that have been preferably engineered.
  • the Sortase enzyme is Sortase A or Sortase B.
  • the PCA is a specific recognition sequence for a ligase receptor substrate.
  • the PCA comprises at least one tandemly linked one or more unit structures selected from the group consisting of glycine and alanine.
  • the PCA comprises 1-100 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine.
  • the PCA comprises 1-50 serially connected one or more unit junctions selected from the group consisting of Structure: glycine and alanine.
  • the PCA comprises from 1 to 20 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine.
  • the PCA comprises five serially linked one or more unit structures selected from the group consisting of glycine and alanine.
  • the PCA comprises three serially linked one or more unit structures selected from the group consisting of glycine and alanine.
  • LA1, LA2 are the junction regions, and a, p are independently 0 or 1, that is, LA1 and LA2 may exist independently or not.
  • LA1 is the junction of PCA and CCA'
  • LA2 is the junction of the -S- group and Y.
  • CCA' is a chemical coupling zone. Represents a single or double key. In certain embodiments, Represents a single key.
  • Y is a loading material selected from the group consisting of a nucleic acid sequence, a short peptide sequence, a polypeptide, a protein, a small molecule compound, and a biological substance.
  • Y is a nucleic acid sequence, nucleic acid analog, label, tag or drug, and the like.
  • Y is a radioactive label, a fluorescent label, an affinity purification tag, a tracer molecule or a small molecule compound, and the like.
  • Y is a cytotoxin.
  • Y is maytansin or a derivative thereof, Auristatin or a derivative thereof, epothilone or an analog thereof, paclitaxel or a derivative thereof, or a vinblastine Compounds, etc. In certain embodiments, Y is maytansin or a derivative thereof.
  • z is any integer between 1 and 1000.
  • z is any integer between 1 and 100, 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 1 to 5.
  • the invention provides a compound as shown below:
  • n any integer between 1 and 100, for example, n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20, and the like.
  • m is any integer between 0 or 1-1000, for example, m can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100, etc.
  • the invention provides a composition comprising one or more of the above compounds, which is prepared by the following steps:
  • Solution or A solution of tris (hydroxymethyl) aminomethane or other solution that promotes the ring opening reaction is added to the solution.
  • the above steps further comprise purifying the prepared product by HPLC. In certain embodiments, the above steps further comprise purifying the prepared product by semi-preparative/preparative HPLC. In certain embodiments, the total content of the compound of formula (I), formula (II), formula (III) or formula (IV) in the composition prepared according to the above steps exceeds 50% by mole, for example More than 60% by mole, 70% by mole, 80% by mole, 85% by mole, 90% by mole, 95% by mole, 99% by mole or more.
  • the present invention provides a compound of the formula (V), (VI), (VII) or (VIII) or a pharmaceutically acceptable salt thereof:
  • A is a protein, a peptide, a signal transduction factor, a cell proliferation factor, an immunoglobulin or an antibody.
  • the antibody is a recombinantly produced monoclonal antibody, chimeric antibody, humanized antibody, antibody fragment, and antibody-like (eg, Fab, ScFv, minibody, diabody, nanobody, etc.).
  • A is an anti-ErbB2/Her2 antibody.
  • a compound of formula (V), formula (VI), formula (VII) or formula (VIII) of the invention is capable of specifically binding to the extracellular domain of the Her2 receptor and inhibiting ErbB2/Her2 Growth of receptor-positive tumor cells.
  • LA1, LA2, and LA3 are each independently a connection region.
  • LA1 is the junction of PCA and CCA'
  • LA2 is the junction of the -S- group and Y
  • LA3 is the junction of A and F.
  • LA3 comprises from 1 to 100 one or more unit structures selected from the group consisting of glycine and alanine; preferably, LA3 comprises from 1 to 50 tandemly linked one or more unit structures selected from the group consisting of : glycine and alanine. More preferably, LA3 comprises 1-20 one or more unit structures selected from the group consisting of: Alanine and alanine. More preferably, LA3 comprises five monovalently linked one or more unit structures selected from the group consisting of glycine and alanine.
  • a, b, and p are each independently 0 or 1, that is, LA1, LA2, and LA3 may exist independently or not.
  • PCA and F are specific recognition sequences of ligase, respectively, and PCA can specifically bind to F under the action of the ligase.
  • the ligases include, but are not limited to, various natural Sortase enzymes and various novel transpeptidases that have been preferably engineered.
  • the Sortase enzyme is Sortase A or Sortase B.
  • F is a specific recognition sequence for a ligase donor substrate and PCA is a specific recognition sequence for a ligase receptor substrate.
  • F is a specific recognition sequence for a ligase receptor substrate and PCA is a specific recognition sequence for a ligase donor substrate.
  • the PCA comprises at least one tandemly linked one or more unit structures selected from the group consisting of glycine and alanine. In certain embodiments, the PCA comprises 1-100 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine. Preferably, the PCA comprises from 1 to 50 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine. More preferably, the PCA comprises from 1 to 20 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine. More preferably, the PCA comprises five serially linked one or more unit structures selected from the group consisting of glycine and alanine.
  • F is attached to the C-terminus of the A heavy or light chain by LA3 or directly covalently.
  • F is X 1 X 2 X 3 TX 4 X 5 , wherein X 1 is leucine or asparagine, X 2 is valine or alanine, and X 3 is any natural or non- A natural amino acid, T is threonine, X 4 represents glycine, serine or asparagine or is absent, X 5 is any natural or non-natural amino acid or is absent.
  • F is LPX 3 T or LPX 3 TGG, wherein L is leucine, P is valine, X 3 is any natural or non-natural amino acid, T is threonine, and G is glycine.
  • CCA' is a chemical coupling zone. Represents a single or double key. In certain embodiments, Represents a single key.
  • Y is a loading material selected from the group consisting of hydrogen, nucleic acid sequences, short peptide sequences, polypeptides, proteins, compounds, and biological materials.
  • Y is a nucleic acid sequence, nucleic acid analog, label, tag or drug, and the like.
  • Y is a radioactive label, a fluorescent label, an affinity purification tag, a tracer molecule or a small molecule compound, and the like.
  • Y is a cytotoxin.
  • Y is maytansin or a derivative thereof, Auristatin or a derivative thereof, epothilone or an analog thereof, paclitaxel or a derivative thereof, or a vinblastine Compounds, etc.
  • Y It is a lignin or a derivative thereof.
  • z is any integer between 1 and 1000.
  • z is any integer between 1 and 100, 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 1 to 5.
  • d is any integer between 1 and 20, for example, d may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, etc.
  • the invention provides a compound as shown below:
  • Ab is a sequence as shown in SEQ ID NOs: 1-8, z represents any integer between 1-20, n represents any integer between 1-100, and m is between 0 or 1-1000 Any integer, d represents any integer between 1 and 20, and LA3 comprises from 1 to 100 one or more unit structures selected from the group consisting of glycine and alanine; b is independently 0 or 1 That is, LA3 may exist independently or not.
  • the invention provides a composition comprising the above compound, which is prepared by the following steps:
  • the total content of the compound of formula (V), formula (VI), formula (VII) or formula (VIII) in the composition prepared according to the above procedure exceeds 50% by mole, for example More than 60% by mole, 70% by mole, 80% by mole, 85% by mole, 90% by mole, 95% by mole, 99% by mole or more.
  • the invention provides a method of inhibiting cell proliferation in an animal comprising treating the animal with a compound or composition of the invention.
  • the animal is a mammal. In certain embodiments, the animal is a human.
  • the invention provides the use of a compound of the invention in the manufacture of a medicament for the treatment or prevention of a human disease.
  • the disease comprises a tumor and an autoimmune disease.
  • the cell surface of the tumor has a specific antigen or receptor protein that recognizes and binds to the compound or composition.
  • the specific antigen or receptor protein on the cell surface of the tumor is ErbB2/Her2.
  • the tumor is breast cancer, gastric cancer, ovarian cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, or esophageal cancer.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by formula (V), formula (VI), formula (VII), or formula (VIII), or a pharmaceutically acceptable salt thereof, And a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is a lyophilized powder injection or injection.
  • the invention provides a perfect coupling system to solve the problem of instability and heterogeneity of current ADC drug linkers.
  • the solution provided by the invention can also be applied to the preparation of targeted nucleic acid drugs, the preparation of targeted tracing diagnostic reagents and the like.
  • the present invention encompasses a series of linkers and methods for their preparation, Linker-Payload intermediates and methods for their preparation, linker-to-toxin intermediates in a ring-opening stable form, and methods for their preparation.
  • the invention comprises a series of genetically engineered Herceptin or other anti-human ErbB2/Her2 based antibodies (Ab), linkers and modified maytansinoids and derivatives or auristatin (Auristatin)
  • Abs anti-human ErbB2/Her2 based antibodies
  • Auristatin auristatin
  • ligase refers to a transpeptidase, including but not limited to various natural Sortase enzymes (including A, B, C, D, L. plantarum Sortase, etc., see patent US20110321183A1) and various modified novels. Peptidase.
  • the coupling reaction is realized by biological enzyme catalysis, the reaction conditions are mild, the physical and chemical damage of the antibody during the coupling process is reduced, the preparation process and the process are more optimized, and the industrialization is easy to upgrade, which is beneficial to the quality control of the ADC product.
  • LDC technology is the efficient coupling of the linker-cytotoxin intermediate to specific sites of the antibody by means of bioenzyme catalysis, which ensures a high degree of homogeneity of the prepared ADC drug.
  • the ring opening reaction of the succinimide ring is carried out during the preparation of the linker-cytotoxin intermediate, and no macromolecular antibody is involved.
  • This method has two advantages: on the one hand, the ring-opening reaction is carried out in the state of a small molecule compound, and the hydrolysis conditions of the ring-opening hydrolysis condition after the antibody is coupled with the cytotoxin can be There are more flexible options, no need to worry about the damage of antibody protein; on the other hand, even if the ring-opening reaction of the succinimide ring in the linker-cytotoxin molecule is incomplete, the ring-opening product is easy to be combined with the unopened product.
  • the separation is carried out by conventional separation means such as HPLC to obtain a highly purified ring-opening product.
  • the invention is applicable to the stable preparation of any ADC drug containing a thiosuccinimide structure, a targeted nucleic acid drug and a targeted tracer.
  • the present invention relates to a series of linkers having a bidirectional ligation function, characterized by a Protein Conjugation Area (PCA), a Linker Area 1 (LA1) and a Chemical Conjugation Area (CCA). 3 parts, the structure is shown as
  • PCA Protein Conjugation Area
  • LA1 Linker Area 1
  • CCA Chemical Conjugation Area
  • PCA may be a suitable acceptor substrate for the Sortase A enzyme, including but not limited to the oligoglycine (Gly) sequence Gn (n is typically 1-100), and the alpha-carboxyl group of the C-terminal amino acid is used to couple to the LA.
  • PCA may also be a suitable receptor substrate for other Sortase enzymes or engineered preferred enzymes, such as an oligoalanine (Ala) sequence or an oligo-glycine/alanine hybrid sequence.
  • LA1 is the interface between PCA and CCA, and a is 0 or 1, meaning that LA1 may or may not exist.
  • the LA1 structure is as follows:
  • R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are the same or different and are H, a linear alkyl group having 1 to 6 carbon atoms, having 3 to 6 carbon atoms Branched or cyclic alkyl, linear, branched or cyclic alkenyl or alkynyl group having 2 to 6 carbon atoms, charged substituent selected from anions and cations - said anion selected from SO3, X -SO3-, OPO32-, X-OPO32-, PO32-, X-PO32-, CO2- and the cation are selected from a nitrogen-containing heterocycle, N+R11R12R13 or X-N+R11R12R13, or a phenyl group, wherein: R11, R12 and R13 are the same or different and are H, a linear alkyl group having 1 to 6 carbon atoms or a branched or cyclic alkyl group having 3 to 6 carbon atoms;
  • ⁇ , ⁇ and ⁇ are 0 or an integer from 1 to 4;
  • B is a phenyl or substituted phenyl group, wherein the substituent is a linear alkyl group having 1 to 6 carbon atoms, or a branched or cyclic alkyl group having 3 to 6 carbon atoms, or an anion and a cation selected from the group consisting of a charged substituent selected from the group consisting of SO3-, X-SO3-, OPO32-, X-OPO32-, PO32-, X-PO32-, CO2- and said cation selected from the group consisting of nitrogen-containing heterocycles, N+ R11R12R13 or X-N+R11R12R13, wherein X has the same definition as above, and wherein y is 0 or 1;
  • P is an optional polyethylene glycol unit of the formula (OCH2CH2)z, wherein z is 0 or 1 to 1000 The integer.
  • LA2 in the present invention may have the same definition as LA1, or may be a peptide or peptoid formed by an amide bond between a natural amino acid and a non-natural amino acid, or may be an appropriate combination of the above two definitions.
  • LA3 comprises from 1 to 100 one or more unit structures selected from the group consisting of glycine and alanine.
  • CCA includes CCA' and contains appropriate functional groups, which can be combined with small molecule compounds, nucleic acids via amide bonds, disulfide bonds, thioether bonds, thioester bonds, peptide bonds, oximes, ester bonds, ether bonds or urethane bonds. Molecular, tracer molecules, etc. are covalently coupled.
  • Preferred chemical groups include, but are not limited to, N-succinimidyl ester and N-sulfosuccinimidyl ester (suitable for reaction with primary amines); maleimide groups (suitable for reaction with sulfhydryl groups) Reaction); pyridyldithio (suitable for reaction with sulfhydryl groups to form disulfide bonds); and alkylhalide or haloacetyl (suitable for reaction with sulfhydryl groups); isocyanate ) (suitable for reaction with a hydroxyl group).
  • a preferred class of CCA1 of the linker of the present invention comprises a peptide sequence (forming an amide bond by condensation of an alpha group with a carboxyl group), which must contain Lysine (number 1-100), this peptide
  • Lysine number 1-100
  • the alpha-position amine group of the N-terminal amino acid forms an amide bond with LA (or directly with PCA).
  • the ⁇ -position amine group on the oligo-lysine chain can directly introduce the maleimide functional group through a suitable bifunctional cross-linker;
  • the ⁇ -position amine group can be used to form an amide bond with the ⁇ -position carboxyl group of another lysine to form a branch, and thus the ⁇ -position and the ⁇ -position amine group of the branched lysine can be directly introduced through a suitable bifunctional crosslinking agent.
  • Maleimide functional group By analogy, this class can be made by increasing the number of backbone oligolysines and extending the branching structure of the side chain lysine.
  • bifunctional crosslinking reagents capable of introducing a maleimido functional group include, but are not limited to, a crosslinking reagent comprising a maleimide group having a 4-(N-maleimidomethyl)cyclohexane N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), SMCC "long-chain” analogue N-( ⁇ -maleimido N-[alpha-maleimidoacetoxy]Succinimide ester (AMAS), 4-maleimidobutyrylbutyric acid N-succinimide ester (N-gamma-Maleimidobutyryl-oxysuccinimide ester , GMBS), m-maleimide benzoyl-N-hydroxysuccinimide ester (3-MaleiMidobenzoic acid N-hydroxysuccini
  • linker satisfying the above requirements are shown in Figures 3-6, but are not limited thereto.
  • the above-mentioned linkers 1, 2, 3, 4 all have a maleimide structure and can be rapidly and quantitatively coupled with any thiol-containing substance (see 'loading substance' below) to form a thiosuccinimide structure.
  • CCA2 in the linkers of the present invention contains an octagonal cysteine (Cysteine) sequence (Cysteine number 1-100, which forms an amide bond by condensation of an amino group with a carboxyl group), N-terminal cysteine
  • Cysteine Cysteine number 1-100, which forms an amide bond by condensation of an amino group with a carboxyl group
  • the amide bond is formed by its alpha-position amine group and LA (or directly with PCA), and its side chain thiol group can be coupled to a molecule containing a maleimide functional group.
  • the linkers of the present invention can be realized by a conventional polypeptide solid phase synthesis method with appropriate adjustment, and are composed of the following steps:
  • Rink amide-MBHA Resin was used as a carrier for the C-terminal amide sequence synthesis, and a king resin was used for the C-terminal carboxylic acid sequence.
  • Linking side chain SMCC or other bifunctional molecules According to different Lys side chain protecting groups, they are removed by different methods. For example, catalytic hydrogenation is used to remove Z, and hydrazine hydrate is used to remove ivDde. The activated SMCC or other bifunctional molecules are then directly accessed. If no side chain modification is required, the reaction ends here.
  • the payload in the present invention may be a small molecule compound, a nucleic acid, a nucleic acid analog, a tracer molecule or the like (including a caged radionuclide and a fluorescent molecule, etc.), and a cytotoxin is preferred among the small molecule compounds.
  • the cytotoxin is selected from the group consisting of microtubule inhibitors such as paclitaxel and its derivatives, maytansin and its derivatives, auristatin and its derivatives, epothilone and its analogues, combretastatin A- 4phosphate, Combretastatin A-4 and its derivatives, sulfonamides, vinblastine compounds such as vinblastine, vincristine, vindesine, vinorelbine, Changchun Vinflunine, vinglycinate, anhy-drovinblastine, Dolastatins 10 and its analogues, halichaxin B and eribulin, indole-3-oxalic acid amides, substituted hydrazine- 3-oxalyl, podophyllotoxin, 7-diethylamino-3-(2'-benzoxazolyl)-coumarin (DBC), Discodermolide, Laulimalide; DNA topoisome
  • Preferred cytotoxins of the invention are maytansin and its derivatives DM1, DM4 and the Auristatin derivatives MMAE, MMAF, MMAD and the like.
  • the above preferred linker containing CCA1 has a maleimide ring structure in CCA1, and can form a thiosuccinimide structure with any thiol group-containing molecule, and the thiol group-containing substance includes a small molecule compound, a short peptide, and a polypeptide. , peptidomimetics, proteins, nucleic acids, and nucleic acid-like molecules.
  • the above-mentioned coupling intermediate can be fully treated by the conditions of the succinimide ring opening, thereby forming a corresponding ring-opening stable form of the intermediate molecule, and the structural formula is as follows:
  • CCA1open-Y has the following structure:
  • the preferred linker of the 1, 2, 3, 4 molecule of the present invention is incubated with a solution of the preferred cytotoxin maytansin derivative DM1, respectively, to form the following linker-DM1 containing a thiosuccinimide structure.
  • the structure of the molecules is shown in Figure 11-14.
  • the linkers 1, 2, 3, 4 are each coupled to a preferred cytotoxin DM1, and a ring-opening reaction results in a molecule as shown in Figures 15-18.
  • the ring opening reaction can be treated by any of the following conditions, but is not limited thereto: 0.1-0.5 M Lys, 0.1-0.5 MArg, 0.1-0.5 M Tris Base, 0.1-0.5 M sodium hydrogencarbonate, 0.1-0.5 M sodium carbonate, 0.1- 0.5M sodium borate, reacted at room temperature for 2-12h.
  • the above conditions are such that the ring opening efficiency can reach 10%, 20%, 30%, 50%, 60%, 70%, 80%, 90% or close to 100%.
  • the above preferred linker containing CCA2 has a thiol group in CCA2, and can form a thiosuccinimide structure with any molecule containing a maleimide, and the substance containing a maleimide includes a small molecule compound and a short peptide. , peptides, peptidomimetics, proteins, nucleic acids, and nucleic acid-like molecules.
  • the above-mentioned coupling intermediate can be fully utilized to treat the succinimide ring opening condition, thereby forming a corresponding open-loop stable form of the intermediate, the structural formula is as follows:
  • CCA2open-Y has the following structure:
  • linkers 5, 6, 7, and 8 are respectively coupled with MC-VC-PAB-MMAE to form the following linker-MMAE intermediate molecules containing a thiosuccinimide structure, and their structures are as shown in Figure 19-22.
  • the cytotoxins used in the present invention include, but are not limited to, MMAE.
  • the linkers 5, 6, 7, and 8 are respectively coupled to the preferred cytotoxin MMAE, and the corresponding molecules are obtained by ring-opening reaction, and the structures are shown in Figures 23-26, respectively.
  • the ring opening reaction can be treated by any of the following conditions, but is not limited thereto: 0.1-0.5 MLys, 0.1-0.5 M Arg, 0.1-0.5 M Tris Base, 0.1-0.5 M sodium hydrogencarbonate, 0.1-0.5 M sodium carbonate, 0.1- 0.5M sodium borate, reacted at room temperature for 2-12h.
  • the above conditions are such that the ring opening efficiency can reach 10%, 20%, 30%, 50%, 60%, 70%, 80%, 90% or close to 100%.
  • the antibody referred to in the present invention refers to a monoclonal antibody, a chimeric antibody, a humanized antibody, an antibody fragment, and an antibody-like antibody (such as Fab, ScFv, minibody, diabody, nanobody, etc.) which are recombinantly produced.
  • the antibody of the present invention is a series of genetically engineered recombinant antibodies having a C-terminus of a heavy chain and/or a light chain containing a unique modification based on a ligase recognition site sequence, wherein the ligase is a transpeptidase, Including but not limited to a variety of natural Sortase enzymes (including A, B, C, D, L. plantarum Sortase Etc. See patent US20110321183A1) and various novel transpeptidases which have been preferably modified.
  • the ligase recognition site may be a typical recognition sequence of the Sortase A enzyme derived from Staphylococcus aureus (LPXTG), wherein X may be any natural or non-natural amino acid; the ligase recognition site may also be of other types of Sortase.
  • LPXTG Staphylococcus aureus
  • the recognition sequence (the recognition sequence of the donor substrate of the Sortase enzyme, the Sortase B of Staphylococcus aureus is NPQTN, the Sortase B of Bacillus anthracis is NPKTG, the Sortase A of Streptococcus pyogenes is LPXTG, the Sortase subfamily 5 of Streptomyces coelicolor is LAXTG, and the Sortase of Lactobacillus plantarum is LPQTSEQ, etc.; the ligase recognition site may also be a novel recognition sequence for other preferred transpeptidase enzymes after artificial selection).
  • the antibody of the present invention is further preferably a series of genetically engineered anti-human ErbB2/HER2 antibodies selected from the group consisting of monoclonal antibodies, chimeric antibodies, humanized antibodies, antibody fragments, and antibody-like antibodies. (such as Fab, ScFv, minibody, diabody, nanobody, etc.).
  • the anti-ErbB2/HER2 antibody specifically binds to the extracellular domain of the ErbB2/HER2 receptor and inhibits the growth of tumor cells that express the Her2 receptor in vivo and in vitro.
  • the light chain (LC) contained therein has a wild type (LC), a C-terminal direct introduction of a ligase recognition sequence LPETGG (LCCT), a C-terminal introduction of a short junction region (Gly-Ala) plus a ligase.
  • the recognition sequence LPETGG is modified (LCCT L ) in three types; the heavy chain (HC) contained therein has a wild type (HC), the C-terminus is directly introduced into the ligase recognition sequence LPETGG (HCCT), and the C-terminal introduction is short.
  • junction region (Gly-Ala) plus three modifications of the ligase recognition sequence LPETGG (HCCT L ).
  • the combination of the above heavy and light chains can form three preferred antibody molecules.
  • a total of eight preferred antibody molecules are formed by combining various heavy and light chains, and the amino acid residue sequences are detailed in the amino acid sequence table.
  • the ADC drug attachment site prepared by traditional chemical coupling is uncertain, and the product DAR (Drug Antibody Ratio) has a wide distribution range, and the drug heterogeneity is serious, and it cannot be further purified.
  • the ADC drug prepared by the present invention is site-specifically coupled.
  • Step 1 Prepare suitable formulas of formula (I) and (II), (III) and (IV) according to the foregoing steps.
  • Linker-cytotoxin open-loop intermediate Regardless of the yield of the succinimide ring ring opening reaction, high purity separation and preparation of the ring-opening intermediate is accomplished by semi-preparative/preparative HPLC or other suitable separation means.
  • Step 2 The genetically engineered recombinant antibody comprising a ligase-specific recognition sequence is expressed and purified by CHO cells or other suitable mammalian cell culture systems.
  • Step 3 A coupling reaction of a recombinant antibody (or antibody) with a linker-cytotoxin ring-opening intermediate.
  • Recombinant antibodies with a specific recognition site at the C-terminus of the light and/or heavy chain and the linker-cytotoxin intermediate are subjected to a coupling reaction under suitable catalytic reaction conditions by a suitable ligase (or ligase combination).
  • the antibody molecule and the linker-cytotoxin intermediate are catalyzed by a ligase to obtain a series of preferred ADC drugs, exemplified by Figures 27-32. See the embodiment for details.
  • the ADC drugs provided by the present invention can be analyzed in a variety of ways.
  • the reaction efficiency can be analyzed by SDS-PAGE.
  • the precise molecular structure can be analyzed by high-precision molecular weight mass spectrometry (ESI-MS).
  • the DAR distribution can be analyzed by hydrophobic interaction high performance liquid chromatography (HIC-HPLC). Analysis was carried out by molecular sieve high performance liquid chromatography (SEC-HPLC).
  • the present invention provides a method for determining the binding and affinity of an ADC drug to a specific antigen on a tumor cell surface for screening and identifying an ADC drug that efficiently binds to a specific antigen or receptor on the surface of a tumor cell.
  • One specific protocol is to incubate the ADC candidate drug GQ1001 with cells from a stable breast cancer cell line for a certain period of time (10-60 min), and to determine the affinity of the ADC candidate drug GQ1001 and the ErbB2/Her2 receptor on the surface of breast cancer cells by FACS.
  • the present invention determines the cytotoxicity or cell proliferation inhibitory activity of a candidate ADC drug by: having a tumor associated antigen or being subjected to Body protein mammalian cells (eg ErbB2/Her2) Highly expressed or underexpressed breast cancer cells were incubated with candidate ADC drugs, cultured for about 12-120 h, and Cell viter Glo method was used to determine cell viability.
  • a tumor associated antigen e.g ErbB2/Her2
  • Body protein mammalian cells eg ErbB2/Her2
  • Highly expressed or underexpressed breast cancer cells were incubated with candidate ADC drugs, cultured for about 12-120 h, and Cell viter Glo method was used to determine cell viability.
  • One of the examples is the ADC drug GQ1001 and human breast cancer cells (such as BT474, HCC1954, SK-BR-3, MCF-7, MDA-MB-468), human ovarian cancer cells (SK-OV-3), human gastric cancer.
  • the cells (NCI-N87) were incubated for 24-120 h, and the Cell Titer Glo method was used to detect ATP in the cells, and the amount of ATP was used to reflect the cell viability. The results showed that GQ1001 selectively inhibited the proliferation of ErbB2/HER2 overexpressing cells.
  • Rats were injected with 5-50 mg/kg of candidate ADC drugs in the tail vein. Blood samples were taken at different time points after administration. The concentration of candidate ADC drugs in serum was determined by ELISA.
  • the SD rats are given GQ1001 or Kadcyla by a single injection in the tail vein, and the blood of the rats is collected at different time points from 1 hour to 28 days after administration, and the concentration of GQ1001 or Kadcyla in the serum is detected by ELISA. The results showed that there was no significant difference in the time course of the concentration of GQ1001 and Kadcyla in the rats.
  • the invention measures the in vivo anti-tumor effect of the ADC drug after the candidate ADC drug treatment is applied to the nude mouse xenograft tumor model.
  • One of the examples used human breast cancer cells to make tumors, and tumor growth was measured after a single injection of 0.5-50 mg/kg ADC drug GQ1001 via a tail vein. The results confirmed that a single intravenous injection of GQ1001 in the 0.5-50 mg/kg dose range significantly inhibited the proliferation of ErbB2/Her2 positive tumor cells.
  • the present invention evaluates the acute toxicity of candidate ADC drugs in rats.
  • Female Sprague-Dawley rats were given a large dose (60 mg/kg or more) of candidate ADC drugs, and then observed and analyzed the effects of drugs on rats, such as body weight, clinical symptoms, hematology, clinical biochemistry and histopathology.
  • the indicators examine the toxicity of candidate ADC drugs. It was found that at the same dose level (60 mg/kg), the toxicity of the ADC drug GQ1001 was significantly less than that of Kadcyla.
  • the invention provides a special kind of linker, which can be used for protein, especially the connection of various antibodies with small molecular compounds, peptides, nucleic acids, tracers and the like, and is prepared for scientific research and clinical diagnosis. And various couplings for treatment.
  • the linker provided by the invention can be used for the fixed-point connection of a small molecule compound with an antibody, and the preparation is highly uniform. Quality ADC drugs.
  • the present invention provides a class of ADC drugs formed by site-directing attachment of small molecule cytotoxic drugs, particularly maytansin and its derivatives, to anti-human ErbB2/Her2 antibodies by the above-described linkers.
  • the ADC drugs of the invention are useful in the treatment of a variety of diseases or disorders, such as tumors and autoimmune diseases.
  • Tumors that are sensitive to ADC drug therapy include tumors characterized by specific tumor-associated antigens or cell surface receptors that are specifically recognized by antibodies in ADC drugs and then killed by small molecule cytotoxic drugs linked to ADC drugs. .
  • the anti-human ErbB2/Her2 antibody provided by the invention is combined with a small molecule cytotoxic drug to form an ADC drug GQ1001 which specifically binds to ErbB2/Her2 on the surface of tumor cells, thereby selectively killing tumor cells with high expression of ErbB2/Her2, and treating various kinds of tumor cells.
  • ErbB2/Her2 positive tumors including but not limited to breast cancer, gastric cancer, lung cancer, ovarian cancer and the like.
  • the linker provided by the present invention is suitable for site-specific coupling of various proteins, especially antibodies and small molecules, peptides, nucleic acids, fluorescent tracers, indicators and the like.
  • the coupling condition is mild, has no effect on the activity of biomolecules, and has broad application prospects.
  • the linker provided by the present invention is a succinimide ring-opening structure, which is stable in mammals compared to a closed-loop structure, and the linked cytotoxin is not easily rich in cysteine, glutathione and white in vivo.
  • the ADC drug prepared by the linker can be more stably present in the body, and solves the problem that small molecules in the current ADC drug are easy to fall off.
  • the ADC drug provided by the invention is a fixed-point coupling product, which is highly homogeneous. Compared with the conventional non-spot chemical coupling product, the ADC drug provided by the invention has obvious improvement in quality control and drug safety. Fundamentally solved the problem of ADC drug heterogeneity that plagued the industry.
  • FIG. 1 Schematic diagram of ligase catalytic coupling technology
  • Figure 14 Molecular schematic of the linker 4-DM1 intermediate (n is an integer between 1 and 100, m is any integer between 0 or 1-1000, and X is a -OH or -NH 2 group)
  • Figure 15 Schematic diagram of the ring-opening molecular structure of the linker 1-DM1 intermediate (n is an integer between 1 and 100, X is a -OH or -NH 2 group; A and B are isomers)
  • Figure 16 Schematic diagram of the ring-opened molecular structure of the linker 2-DM1 intermediate (n is an integer between 1 and 100, X is a -OH or -NH 2 group; A and B are isomers)
  • Figure 17 Schematic diagram of the ring-opening molecular structure of the linker 3-DM1 intermediate (n is an integer between 1 and 100, m is any integer between 0 or 1-1000, and X is an -OH or -NH 2 group ;A and B are isomers)
  • Figure 18 is a schematic diagram showing the structure of the ring-opening molecule of the linker 4-DM1 intermediate (n is an integer between 1 and 100, m is an arbitrary integer between 0 or 1-1000, and X is an -OH or -NH 2 group; A and B are isomers)
  • Figure 23 is a schematic diagram showing the ring-opening molecular structure of the 5-mer amide intermediate (n is an integer between 1 and 100, X is a -OH or -NH 2 group; A and B are isomers)
  • Figure 24 is a schematic diagram showing the ring-opened molecular structure of the 6-MMAE intermediate of the linker (n is an integer between 1 and 100, X is an -OH or -NH 2 group; and A and B are isomers)
  • Figure 25 is a schematic diagram showing the ring-opening molecular structure of the linker 7-MMAE intermediate (n is an integer between 1 and 100, X is an -OH or -NH 2 group, and m is an arbitrary integer between 0 or 1-100; A and B are isomers)
  • Figure 26 Schematic diagram of the ring-opened molecular structure of the linker 8-MMAE intermediate (n is an integer between 1 and 100, X is an -OH or -NH 2 group, and m is an integer between 0 or 1-100. ;A and B are isomers)
  • FIG. 27 Molecular schematic of preferred ADC1 (n is an integer between 1 and 100, d is any integer between 1 and 20, and X in the ligase recognition sequence LPXT is glutamic acid (E) or any other natural Ab non-natural amino acid; Ab is an antibody, and LA3 is a junction region comprising 1 to 100 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine; b being independently 0 or 1, respectively. Represents LA3 in the absence or absence; X is an -OH or -NH 2 group; A and B are isomers)
  • Figure 28 Molecular schematic of a preferred ADC2 (n is an integer between 1 and 100, d is any integer between 1 and 20, and X in the ligase recognition sequence LPXT is glutamic acid (E) or any other natural Ab non-natural amino acid; Ab is an antibody, and LA3 is a junction region comprising 1 to 100 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine; b being independently 0 or 1, respectively. Represents LA3 in the absence or absence; X is an -OH or -NH 2 group; A and B are isomers)
  • Figure 29 Molecular schematic of a preferred ADC3 (n is an integer between 1 and 100, d is any integer between 1 and 20, and X in the ligase recognition sequence LPXT is glutamic acid (E) or any other natural /Unnatural amino acid; m is any integer between 0 or 1-1000, Ab is an antibody, LA3 is a junction region, and includes 1 to 100 tandemly linked one or more unit structures selected from the group consisting of glycine and C Is a group of 0 or 1 independently, representing LA3 in the absence or absence; X is a -OH or -NH 2 group; A and B are isomers)
  • Figure 30 Molecular schematic of a preferred ADC4 (n is an integer between 1 and 100, d is any integer between 1 and 20, and X in the ligase recognition sequence LPXT is glutamic acid (E) or any other natural /Unnatural amino acid; m is any integer between 0 or 1-1000, Ab is an antibody, LA3 is a junction region, and includes 1 to 100 tandemly linked one or more unit structures selected from the group consisting of glycine and C Is a group of 0 or 1 independently, representing LA3 in the absence or absence; X is a -OH or -NH 2 group; A and B are isomers)
  • Figure 31 Molecular schematic of a preferred ADC5 (n is an integer between 1 and 100, d is any integer between 1 and 20, and the X in the ligase recognition sequence LPXT is glutamic acid (E) or any other natural Ab non-natural amino acid; Ab is an antibody, and LA3 is a junction region comprising 1 to 100 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine; b being independently 0 or 1, respectively. Represents LA3 in the absence or absence; X is an -OH or -NH 2 group; A and B are isomers)
  • Figure 32 Molecular schematic of a preferred ADC6 (n is an integer between 1 and 100, d is any integer between 1 and 20, and the X in the ligase recognition sequence LPXT is glutamic acid (E) or any other natural Ab non-natural amino acid; Ab is an antibody, and LA3 is a junction region comprising 1 to 100 tandemly linked one or more unit structures selected from the group consisting of glycine and alanine; b being independently 0 or 1, respectively. Represents LA3 in the absence or absence; X is an -OH or -NH 2 group; A and B are isomers)
  • FIG 39 Results of ADC drug GQ1001 light chain high precision molecular weight mass spectrometry (ESI-MS).
  • A Mass spectrum of light chain;
  • B relative molecular weight of light chain after convolution with ProMass 2.8 software (25281)
  • FIG 51 Pharmacokinetic analysis of a single intravenous injection of GQ1001, Kadcyla in rats. SD rats were injected with GQ1001 (10mg/kg) or Kadcyla (10mg/kg) via tail vein. The concentration of total ADC drugs in rat serum was detected by ELISA.
  • FIG 53 Body weight changes after a single intravenous injection of GQ1001 and Kadcyla in rats. Healthy adult female rats were given GQ1001 (6, 60mg/kg) or Kadcyla (60mg/kg) by single injection in the tail vein. There was no significant difference in weight gain between the GQ1001 group and the vehicle control group (P>0.05). ), Kadcyla administration group rats significantly reduced body weight (P ⁇ 0.05 vs Vehicle)
  • FIG 54 Changes in ALT and AST after a single intravenous injection of GQ1001 and Kadcyla in rats. Healthy adult female rats were given GQ1001 (6, 60 mg/kg) or Kadcyla (60 mg/kg) via a single injection in the tail vein. Compared with the vehicle control group, the GQ1001 administration group alanine aminotransferase (ALT) There was no significant difference between ALT and AST in the aspartate aminotransferase (AST) (P>0.05).
  • the plasmid encoding the SEQ ID No. 1 antibody T-LCCT L- HC was transfected into CHO cells and the cell population was constructed, and the cell population with high expression amount was selected, and cultured in a 5-10 L reactor under the culture process of Trastuzumab, and the supernatant was collected.
  • T-LCCT L- HC Purification of T-LCCT L- HC by standard procedure using a combination of MabSelect affinity chromatography and SepharoseS cation exchange chromatography, dissolved in Trastuzumab original drug buffer (5 mM histidine-HCl, 2% Trehalose, 0.009% Polysorbate 20) , PH6.0), divided into frozen storage.
  • the purity of the purified antibody T-LCCT L- HC was 98.5% by SDS-PAGE; the content of the high molecular weight polymer was less than 0.4% by SEC-HPLC; the endotoxin content was less than 0.098 EU/mg.
  • the proportion of open loops is increasing (from 10% to 73%).
  • dissolve, and check its purity and molecular weight by liquid chromatography-mass spectrometry (UPLC-MS); the results are shown in Figure 36 and Figure 37.
  • the antibody T-LCCT L- HC was treated by ultrafiltration or dialysis or desalting column method, and the storage buffer was replaced with 1 ⁇ ligase buffer.
  • the main component of 1X ligase buffer was 50 mM Tris-HCl (pH between 5-8), 150 mM NaCl, with or without CaCl 2 .
  • the antibody T-LCCT L -HC and the linker 2-DM1 intermediate were thoroughly mixed in an appropriate molar ratio (1:1 to 1:100).
  • inject the solid phase coupling column inject the solid phase coupling column.
  • the coupling reaction is carried out at 4-40 ° C for 0.5-20 hours.
  • the solid phase coupling column releases the reaction mixture and is subjected to ultrafiltration or dialysis to remove unreacted pharmaceutical intermediates.
  • the purified ADC drug GQ1001 was stored in Kadcyla original buffer (10 mM Sodium Succinate, pH 5.0; 100 mg/ml Trahelose; 0.1% (w/v) Polysorbate 20; formulated with reference to Kadcyla formulation), stored at 4 ° C or -80 °C.
  • the purity and coupling efficiency of GQ1001 can be detected by SDS-PAGE.
  • the results of SDS-PAGE of GQ1001 are shown in Figure 38.
  • the coupling reaction occurs at the light chain of the antibody T-LCCT L- HC, and the GQ1001 light chain of the cytotoxin DM1 is coupled with the T-coupled cytotoxin.
  • the LCCT L- HC light chain has a significant molecular weight transition; the light chain of the uncoupled cytotoxin is not detected in the coupled product, the coupling efficiency is over 95%, and the purity of the coupled product is as expected.
  • the light chain of the ADC drug GQ1001 was analyzed by high-precision molecular weight mass spectrometry. The results showed that the apparent molecular weight was 25281 and the theoretical molecular weight was 25284, which was in line with expectations. It was confirmed that one cytotoxin molecule was coupled to the end of each light chain.
  • ESI-MS high-precision molecular weight mass spectrometry
  • the distribution of the ADC drug GQ1001DAR was detected using a Butyl-HIC column. The results are shown in Figure 40.
  • the T-LCCT L- HC of the unconjugated cytotoxin is less than 5%.
  • the coupled product is mainly GQ1001 of DAR2.
  • the DAR of the ADC drug GQ1001 is about 1.8.
  • the high molecular weight aggregation of the ADC drug GQ1001 was measured using SEC-column analysis. As shown in Fig. 41, no high molecular weight polymer was detected in the ADC drug GQ1001, and the damage of the antibody by the coupling reaction was almost negligible.
  • Example 9 Effect of ADC drug GQ1001 on tumor cell proliferation at different expression levels of ErbB2/Her2 ring
  • GQ1001, Kadcyla, Herceptin, DM1 at different concentrations (30, 10, 3.333, 1.11, 0.370, 0.123, 0.041, 0.014, 0.005 nM) were added to the cultured overnight cells.
  • Puromycin was added at a concentration of 50 ⁇ M in the control group, and continued at 37 °C. Incubate for 48 to 96 hours.
  • DM1 has a significant inhibitory effect on the proliferation of ErbB2/Her2 high- and low-expressing cells, while Herceptin, GQ1001 only inhibited ErbB2/Her2 high-expressing cells only, but did not significantly inhibit ErbB2/Her2 low-expressing cells.
  • Kadcyla only inhibited ErbB2/Her2 low-expressing cells at high concentrations.
  • GQ1001 10 mg/kg GQ1001 (batch number: 20141128, purity > 98%) or Kadcyla (Lot N1003) was administered by tail vein injection, and the blank control group was injected with an equal volume of PBS (pH 7.4) via the tail vein.
  • Animals with a tumor volume of 130-140 mm 3 were screened and randomly divided into vehicle control group, GQ1001 0.5 mg/kg, 5 mg/kg group, Kacyla 5 mg/kg group and Herceptin 5 mg/kg group, 10 rats in each group. Each group of animals was administered by tail vein injection, and the control group was given an equal volume of vehicle. Tumor volume of each group of animals was measured twice a week for 31 days after administration, and once every 31 days.
  • T is the average time (days) in which the average tumor size of the treatment group reaches a predetermined size (500 mm 3 )
  • C is the average time (days) in which the average tumor value of the control group reaches a predetermined size (500 mm 3 ).
  • the T/C (percentage) value is an indicator of the tumor suppressing effect
  • T is the average tumor volume of each drug treatment group at a fixed time point
  • C is the average tumor volume of the control group at a fixed time point.
  • b.Tumor Growth Inhibition is calculated by dividing the group average tumor volume for the treating group by the group average tumor volume for the control group (T/C).
  • the drug intermediate in the form of a ring is shown in Figure 23.
  • the purity and molecular weight of the drug intermediate (opening ring) were determined by high performance liquid chromatography. The results are shown in Fig. 55, and the isomers could not be separated in the ordinary liquid phase.
  • the ring-opening reaction solution was detected by a MALDI-TOF mass spectrometer to obtain a molecular weight of the series, as shown in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/CN2015/077887 2014-04-29 2015-04-29 一种新型的稳定型抗体药物耦联物及其制备方法和用途 Ceased WO2015165413A1 (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES15786402T ES2736505T3 (es) 2014-04-29 2015-04-29 Nuevo conjugado estable de anticuerpo-fármaco, método de preparación y uso del mismo
AU2015252518A AU2015252518B2 (en) 2014-04-29 2015-04-29 New stable antibody-drug conjugate, preparation method therefor, and use thereof
CN201580023609.3A CN106856656B (zh) 2014-04-29 2015-04-29 一种稳定型抗体药物耦联物及其制备方法和用途
JP2016563404A JP6666264B2 (ja) 2014-04-29 2015-04-29 新規安定型抗体薬物複合体の作製およびその応用
EP15786402.6A EP3138568B1 (en) 2014-04-29 2015-04-29 New stable antibody-drug conjugate, preparation method therefor, and use thereof
KR1020167033391A KR102511249B1 (ko) 2014-04-29 2015-04-29 신규한 안정한 항체-약물 복합체, 이의 제조방법 및 이의 용도
US15/307,738 US11040084B2 (en) 2014-04-29 2015-04-29 Stable antibody-drug conjugate, preparation method therefor, and use thereof
EP19157398.9A EP3517114A1 (en) 2014-04-29 2015-04-29 New stable antibody-drug conjugate, preparation method and use thereof
CN202110225700.0A CN112999362B (zh) 2014-04-29 2015-10-09 一种稳定型抗体药物耦联物及其制备方法和用途
AU2020200975A AU2020200975B2 (en) 2014-04-29 2020-02-11 New stable antibody-drug conjugate, preparation method therefor, and use thereof
US17/180,412 US11911434B2 (en) 2014-04-29 2021-02-19 Stable antibody-drug conjugate, preparation method therefor, and use thereof
US17/180,645 US11911435B2 (en) 2014-04-29 2021-02-19 Stable antibody-drug conjugate, preparation method therefor, and use thereof
US18/408,826 US20240156894A1 (en) 2014-04-29 2024-01-10 Stable antibody-drug conjugate, preparation method therefor, and use thereof
US18/410,200 US20240165192A1 (en) 2014-04-29 2024-01-11 Stable antibody-drug conjugate, preparation method therefor, and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410174890.8 2014-04-29
CN201410174890 2014-04-29

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/307,738 A-371-Of-International US11040084B2 (en) 2014-04-29 2015-04-29 Stable antibody-drug conjugate, preparation method therefor, and use thereof
US17/180,645 Continuation US11911435B2 (en) 2014-04-29 2021-02-19 Stable antibody-drug conjugate, preparation method therefor, and use thereof
US17/180,412 Division US11911434B2 (en) 2014-04-29 2021-02-19 Stable antibody-drug conjugate, preparation method therefor, and use thereof

Publications (2)

Publication Number Publication Date
WO2015165413A1 true WO2015165413A1 (zh) 2015-11-05
WO2015165413A8 WO2015165413A8 (zh) 2016-04-14

Family

ID=54358190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/077887 Ceased WO2015165413A1 (zh) 2014-04-29 2015-04-29 一种新型的稳定型抗体药物耦联物及其制备方法和用途

Country Status (8)

Country Link
US (5) US11040084B2 (https=)
EP (2) EP3138568B1 (https=)
JP (2) JP6666264B2 (https=)
KR (1) KR102511249B1 (https=)
CN (2) CN106856656B (https=)
AU (2) AU2015252518B2 (https=)
ES (1) ES2736505T3 (https=)
WO (1) WO2015165413A1 (https=)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021136475A1 (en) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. A drug conjugate and applications thereof
WO2021136483A1 (en) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2022160156A1 (en) * 2021-01-28 2022-08-04 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
WO2022188743A1 (en) * 2021-03-08 2022-09-15 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-her2 antibody-immune agonist conjugate and applications thereof
WO2022188740A1 (en) * 2021-03-08 2022-09-15 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-immune agonist conjugate and applications thereof
CN115197297A (zh) * 2021-04-14 2022-10-18 启德医药科技（苏州）有限公司 连接子、缀合物及其应用
WO2022228493A1 (zh) * 2021-04-29 2022-11-03 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用
US11547761B1 (en) 2016-07-07 2023-01-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
WO2023088235A1 (en) 2021-11-16 2023-05-25 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2023104134A1 (en) * 2021-12-09 2023-06-15 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-cytokine fusion proteins and applications thereof
WO2024002154A1 (en) * 2022-06-28 2024-01-04 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-fgfr3 antibody conjugate and medical use thereof
WO2024012569A1 (en) * 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024041587A1 (zh) 2022-08-25 2024-02-29 启德医药科技（苏州）有限公司 抗体偶联药物的药物组合物
WO2024078612A1 (en) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linker-payload compound, conjugates and applications thereof
WO2024193570A1 (en) * 2023-03-21 2024-09-26 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and cancer therapy, and use thereof
WO2024213091A1 (en) 2023-04-13 2024-10-17 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof
WO2025149014A1 (en) 2024-01-12 2025-07-17 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6666264B2 (ja) 2014-04-29 2020-03-13 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー．Ｇｅｎｅｑｕａｎｔｕｍ Ｈｅａｌｔｈｃａｒｅ （Ｓｕｚｈｏｕ）Ｃｏ．， Ｌｔｄ． 新規安定型抗体薬物複合体の作製およびその応用
US20230399616A1 (en) * 2020-10-30 2023-12-14 Westlake Therapeutics (Hangzhou) Co. Limited Modified Red Blood Cells and Uses Thereof for Delivering Agents
CN115867283A (zh) * 2020-12-23 2023-03-28 启德医药科技（苏州）有限公司 包含开环硫代琥珀酰亚胺基团、寡肽片段和手性部分的新型异构化合物
WO2023185907A1 (en) * 2022-03-29 2023-10-05 Genequantum Healthcare (Suzhou) Co., Ltd. A freeze-drying process for an ADC
EP4534090A1 (en) 2022-06-02 2025-04-09 Genequantum Healthcare (Suzhou) Co., Ltd. Oligosaccharide linker, linker-supported material comprising oligosaccharide linker, antibody-drug conjugate having sugar chain remodeling, preparation method therefor and use thereof
AU2023296781A1 (en) 2022-07-01 2025-02-13 Genequantum Healthcare (Suzhou) Co., Ltd. Immobilized endoglycosidase fusion protein and use thereof
WO2024199432A1 (en) * 2023-03-30 2024-10-03 Genequantum Healthcare (Suzhou) Co., Ltd. Site-speicfic orthogonal bioconjugate modality and application thereof
WO2025255054A1 (en) * 2024-06-03 2025-12-11 Darbix Llc Methods and compositions for oligonucleotide bioconjugation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938046A (zh) * 2003-11-06 2007-03-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CN102973947A (zh) * 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241020B2 (en) * 2003-11-20 2007-07-10 Mirror Lite High definition vehicular mirror
SG189817A1 (en) * 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
RU2661083C2 (ru) * 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
CN105722851A (zh) * 2013-04-28 2016-06-29 秦刚 一种新型的连接子及其制备方法和用途
JP6666264B2 (ja) 2014-04-29 2020-03-13 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー．Ｇｅｎｅｑｕａｎｔｕｍ Ｈｅａｌｔｈｃａｒｅ （Ｓｕｚｈｏｕ）Ｃｏ．， Ｌｔｄ． 新規安定型抗体薬物複合体の作製およびその応用
CN107828351B (zh) 2016-09-15 2021-07-27 E·I·内穆尔杜邦公司 用于粘合的导电糊料
EP3821005A4 (en) 2018-07-09 2022-10-26 Genequantum Healthcare (Suzhou) Co., Ltd. AGAINST TROPHOBLAST ANTIGEN 2 (TROP2) SPECIFIC ANTIBODIES
US20230101266A1 (en) 2019-12-31 2023-03-30 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
KR20230147105A (ko) 2021-01-28 2023-10-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 리가제 융합 단백질 및 그 응용
KR102942648B1 (ko) 2021-02-09 2026-03-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 결합 장치 및 결합 화합물을 생성하는 방법
KR102917231B1 (ko) 2021-03-08 2026-01-26 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항체 면역 작용제 접합체 및 이의 적용
CN117177775A (zh) 2021-04-14 2023-12-05 启德医药科技（苏州）有限公司 连接子、缀合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938046A (zh) * 2003-11-06 2007-03-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CN102973947A (zh) * 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11547761B1 (en) 2016-07-07 2023-01-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2021136475A1 (en) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. A drug conjugate and applications thereof
WO2021136483A1 (en) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
CN115175917A (zh) * 2019-12-31 2022-10-11 启德医药科技（苏州）有限公司 药物缀合物及其应用
US11453870B2 (en) 2021-01-28 2022-09-27 Genequantum Healthcare (Suzhou) Co. Ltd. Ligase fusion proteins and application thereof
US12467103B2 (en) 2021-01-28 2025-11-11 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and application thereof
US11834688B2 (en) 2021-01-28 2023-12-05 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and application thereof
WO2022160156A1 (en) * 2021-01-28 2022-08-04 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
WO2022188740A1 (en) * 2021-03-08 2022-09-15 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-immune agonist conjugate and applications thereof
WO2022188743A1 (en) * 2021-03-08 2022-09-15 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-her2 antibody-immune agonist conjugate and applications thereof
AU2022232674B2 (en) * 2021-03-08 2025-08-28 Brightgene Bio-Medical Technology Co., Ltd. Anti-her2 antibody-immune agonist conjugate and applications thereof
EP4304658A1 (en) 2021-03-08 2024-01-17 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-immune agonist conjugate and applications thereof
US11826432B2 (en) * 2021-04-14 2023-11-28 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
US20220395581A1 (en) * 2021-04-14 2022-12-15 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
CN115197297A (zh) * 2021-04-14 2022-10-18 启德医药科技（苏州）有限公司 连接子、缀合物及其应用
WO2022218331A1 (en) * 2021-04-14 2022-10-20 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
WO2022228493A1 (zh) * 2021-04-29 2022-11-03 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用
US11999748B2 (en) 2021-11-16 2024-06-04 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2023088235A1 (en) 2021-11-16 2023-05-25 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN117279932A (zh) * 2021-11-16 2023-12-22 启德医药科技（苏州）有限公司 依沙替康衍生物及其连接子-负载物和缀合物
EP4480957A2 (en) 2021-11-16 2024-12-25 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2023104134A1 (en) * 2021-12-09 2023-06-15 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-cytokine fusion proteins and applications thereof
WO2024002154A1 (en) * 2022-06-28 2024-01-04 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-fgfr3 antibody conjugate and medical use thereof
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024012569A1 (en) * 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
US12539336B2 (en) 2022-07-15 2026-02-03 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024041587A1 (zh) 2022-08-25 2024-02-29 启德医药科技（苏州）有限公司 抗体偶联药物的药物组合物
WO2024078612A1 (en) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linker-payload compound, conjugates and applications thereof
WO2024193570A1 (en) * 2023-03-21 2024-09-26 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and cancer therapy, and use thereof
WO2024213091A1 (en) 2023-04-13 2024-10-17 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof
WO2025149014A1 (en) 2024-01-12 2025-07-17 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
JP7100617B2 (ja) 2022-07-13
US20170112944A1 (en) 2017-04-27
US20210177929A1 (en) 2021-06-17
KR102511249B1 (ko) 2023-03-20
JP6666264B2 (ja) 2020-03-13
US20210401924A1 (en) 2021-12-30
WO2015165413A8 (zh) 2016-04-14
CN106856656B (zh) 2021-01-26
CN112999362B (zh) 2023-11-14
US20240156894A1 (en) 2024-05-16
AU2015252518B2 (en) 2019-11-14
CN112999362A (zh) 2021-06-22
JP2020055828A (ja) 2020-04-09
CN106856656A (zh) 2017-06-16
AU2015252518A1 (en) 2016-12-15
AU2020200975A1 (en) 2020-02-27
JP2017514812A (ja) 2017-06-08
KR20170020328A (ko) 2017-02-22
US11911434B2 (en) 2024-02-27
US11911435B2 (en) 2024-02-27
EP3517114A1 (en) 2019-07-31
US11040084B2 (en) 2021-06-22
AU2020200975B2 (en) 2021-01-28
EP3138568A4 (en) 2017-12-13
ES2736505T3 (es) 2020-01-02
US20240165192A1 (en) 2024-05-23
AU2015252518A2 (en) 2016-12-15
EP3138568B1 (en) 2019-04-17
EP3138568A1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
WO2015165413A1 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
US11833120B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
KR102451080B1 (ko) 효소적 방법을 통한 균일한 항체 약물 접합체
ES2855169T3 (es) Conjugados de polipéptido-anticuerpo derivados de aprotinina
JP2020528069A (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
ES2747273T3 (es) Anticuerpos anti-EpCAM y métodos de uso
JP6876618B2 (ja) 治療目的のための抗体−ウレアーゼコンジュゲート
US20220280615A1 (en) Immune tolerant elastin-like recombinant peptides and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15786402

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016563404

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15307738

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015786402

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015786402

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167033391

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015252518

Country of ref document: AU

Date of ref document: 20150429

Kind code of ref document: A